Literature DB >> 7226174

Attenuation of myocardial acidosis by propranolol during ischaemic arrest and reperfusion: evidence with 31P nuclear magnetic resonance.

G M Pieper, G L Todd, S T Wu, J M Salhany, F C Clayton, R S Eliot.   

Abstract

31P nuclear magnetic resonance (NMR) spectroscopy was used to ascertain whether propranolol could reduce the development of myocardial acidosis during periods of ischaemic arrest and were studied. Cardiac pH progressively declined during ischaemia from a normal 6.97 +/- 0.02 (n = 23) to 6.09 +/- 0.04 or 5.96 +/- 0.04, respectively. Normalisation of pH following reperfusion occurred only in the 35 min ischaemic hearts. Propranolol (1 mg. litre-1) given prior to arrest significantly reduced the magnitude of developing acidosis regardless of the length of ischaemia. Furthermore, it aided in the normalisation of intramyocardial pH upon reperfusion in both groups. Propranolol significantly reduced the magnitude of phosphocreatine (PCr loss normally seen during ischaemic arrest alone, but it did not protect against depletion of ATP. Restoration of PCr reperfusion was virtually complete in all cases, while transient increases in ATP were seen only in those hearts protected by propranolol. In summary, this NMR study demonstrated the first direct evidence that a significant component of the myocardial acidosis caused by global ischaemia and arrest can be blocked by propranolol.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7226174     DOI: 10.1093/cvr/14.11.646

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  10 in total

1.  Oxidative modification by low levels of HOOH can transform myoglobin to an oxidase.

Authors:  Y Osawa; K Korzekwa
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

2.  Comparative study of the effects of acebutolol, atenolol, d-propranolol and dl,-propranolol on the alterations in energy metabolism caused by ischemia and reperfusion: a 31P NMR study on the isolated rat heart.

Authors:  N Lavanchy; J Martin; A Rossi
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 4.  Complementarity of magnetic resonance spectroscopy, positron emission tomography and single photon emission tomography for the in vivo investigation of human cardiac metabolism and neurotransmission.

Authors:  A Syrota; P Jehenson
Journal:  Eur J Nucl Med       Date:  1991

5.  Glycolysis in heart failure: a 31P-NMR and surface fluorometry study.

Authors:  W Auffermann; S T Wu; W W Parmley; J Wikman-Coffelt
Journal:  Basic Res Cardiol       Date:  1990 Jul-Aug       Impact factor: 17.165

6.  Developmental adaptations in cytosolic phosphate content and pH regulation in the sheep heart in vivo.

Authors:  M A Portman; X H Ning
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

7.  Optimal Use of 2',7'-Dichlorofluorescein Diacetate in Cultured Hepatocytes.

Authors:  Megan J Reiniers; Lianne R de Haan; Laurens F Reeskamp; Mans Broekgaarden; Ruurdtje Hoekstra; Rowan F van Golen; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

8.  Creatine kinase overexpression improves ATP kinetics and contractile function in postischemic myocardium.

Authors:  Ashwin Akki; Jason Su; Toshiyuki Yano; Ashish Gupta; Yibin Wang; Michelle K Leppo; Vadappuram P Chacko; Charles Steenbergen; Robert G Weiss
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-10       Impact factor: 4.733

9.  Abnormal phosphocreatine metabolism in perfused diabetic hearts. A 31P nuclear-magnetic-resonance study.

Authors:  G M Pieper; J M Salhany; W J Murray; S T Wu; R S Eliot
Journal:  Biochem J       Date:  1983-02-15       Impact factor: 3.857

10.  Effect of sotalol on ischemic myocardial pH in the dog heart.

Authors:  T Izumi; K Sakai; Y Abiko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-03       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.